We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Encompass Health (EHC): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Encompass Health (EHC - Free Report) will report quarterly earnings of $1.19 per share in its upcoming release, pointing to a year-over-year increase of 6.3%. It is anticipated that revenues will amount to $1.44 billion, exhibiting an increase of 9.2% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Encompass Health metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- Inpatient Rehabilitation' at $1.40 billion. The estimate indicates a year-over-year change of +9.2%.
The combined assessment of analysts suggests that 'Revenues- Outpatient and other' will likely reach $37.63 million. The estimate points to a change of +13% from the year-ago quarter.
It is projected by analysts that the 'Net patient revenue per discharge' will reach $21,472.01. Compared to the current estimate, the company reported $20,990 in the same quarter of the previous year.
The consensus estimate for 'Total Discharges' stands at 65,241. The estimate is in contrast to the year-ago figure of 61,111.
Encompass Health shares have witnessed a change of +6.4% in the past month, in contrast to the Zacks S&P 500 composite's -5.6% move. With a Zacks Rank #3 (Hold), EHC is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q1 Potential of Encompass Health (EHC): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Encompass Health (EHC - Free Report) will report quarterly earnings of $1.19 per share in its upcoming release, pointing to a year-over-year increase of 6.3%. It is anticipated that revenues will amount to $1.44 billion, exhibiting an increase of 9.2% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Encompass Health metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- Inpatient Rehabilitation' at $1.40 billion. The estimate indicates a year-over-year change of +9.2%.
The combined assessment of analysts suggests that 'Revenues- Outpatient and other' will likely reach $37.63 million. The estimate points to a change of +13% from the year-ago quarter.
It is projected by analysts that the 'Net patient revenue per discharge' will reach $21,472.01. Compared to the current estimate, the company reported $20,990 in the same quarter of the previous year.
The consensus estimate for 'Total Discharges' stands at 65,241. The estimate is in contrast to the year-ago figure of 61,111.
View all Key Company Metrics for Encompass Health here>>>
Encompass Health shares have witnessed a change of +6.4% in the past month, in contrast to the Zacks S&P 500 composite's -5.6% move. With a Zacks Rank #3 (Hold), EHC is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>